Merck KGaA announced today that its Merck Serono division has submitted an application to the European Medicines Agency (EMEA) to license Erbitux (cetuximab) for the firstline treatment of epidermal growth factor receptor (EGFR) expressing, advanced or metastatic non-small cell lung cancer (NSCLC).
The details can be read here.
No comments:
Post a Comment